Kang Yuan Pharmaceutical: Received the clinical trial approval letter for Qing Shenting Granules.

Kangyuan Pharmaceuticals announced on April 19th that the company recently received the Drug Clinical Trial Approval Notice for Qing Shen Tong Luo Granules issued by the State Food and Drug Administration. According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial application for Qing Shen Tong Luo Granules accepted on January 28, 2026 meets the relevant requirements for drug registration. Upon further improvement of the clinical trial protocol, it is approved to conduct confirmatory clinical trials for the treatment of rheumatoid arthritis with damp-heat obstruction syndrome.